Eli Lilly and CoXSWX:LLY 100 3-Year ROIIC % is 35.59 as of Dec. 2025, which is 8% above its 10-year median of 33.06. GuruFocus rates XSWX:LLY with a GF Score™ of 100/100 and a GF Value™ of CHF1,115.06 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 942 Drug Manufacturers companies, Eli Lilly and Co ranks better than 78.77% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Eli Lilly and Co's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 35.59%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Eli Lilly and Co's 3-Year ROIIC % or its related term are showing as below:
XSWX:LLY's 3-Year ROIIC % is ranked better than 78.77% of 942
companies
in the Drug Manufacturers industry
Industry Median: 3.72
vs XSWX:LLY: 35.59
Eli Lilly and Co (XSWX:LLY) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Eli Lilly and Co 3-Year ROIIC % Related Terms
Eli Lilly and Co 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Eli Lilly and Co's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:LLY vs JNJ, ABBV, MRK: 3-Year ROIIC % Comparison
For the Drug Manufacturers - General subindustry, Eli Lilly and Co's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eli Lilly and Co 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Eli Lilly and Co's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Eli Lilly and Co (XSWX:LLY) has a 3-Year ROIIC % of 35.59 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Eli Lilly and Co and its competitors. This is near median its historical median of 33.06. According to the industry distribution chart, Eli Lilly and Co ranks #200 out of 942 companies in the Drug Manufacturers industry, placing it in the top 21.2%.
Is Eli Lilly and Co's 3-Year ROIIC % too high?
Eli Lilly and Co's current 3-Year ROIIC % of 35.59 is near median its 10-year median of 33.06. The Drug Manufacturers industry median 3-Year ROIIC % is 3.72. Eli Lilly and Co's value of 35.59 is 856.7% above this industry median. Based on the distribution chart, Eli Lilly and Co ranks #200 out of 942 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Eli Lilly and Co has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's 3-Year ROIIC % compare to JNJ and ABBV?
According to the Drug Manufacturers industry distribution chart, Eli Lilly and Co ranks #200 out of 942 companies for 3-Year ROIIC %. This places Eli Lilly and Co in the top 21% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 3.72. Eli Lilly and Co's value of 35.59 is 856.7% above this benchmark. While the company's 10-year median is 33.06 vs. the industry median of 3.72, Eli Lilly and Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.72, based on 942 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eli Lilly and Co's current 3-Year ROIIC % of 35.59 is 856.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Eli Lilly and Co and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eli Lilly and Co's current 3-Year ROIIC % is 35.59, which is near median its own 10-year median of 33.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (XSWX:LLY) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF1,115.06, compared to a current price of CHF970.00 — trading 13% below its estimated fair value. The current 3-Year ROIIC % is 35.59, which is near median its 10-year median of 33.06 and 856.7% above the Drug Manufacturers industry median of 3.72. Eli Lilly and Co's overall GF Score™ is 100/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Eli Lilly and Co (XSWX:LLY), the current 3-Year ROIIC % is 35.59 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eli Lilly and Co (XSWX:LLY) Overvalued in 2026?
Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued.
The current stock price of CHF970.00 is trading 13% below its estimated GF Value™ of CHF1,115.06.
GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.
Key valuation signals for XSWX:LLY:
3-Year ROIIC %: 35.59 (near median its 10-year median of 33.06)
GF Value™: CHF1,115.06 vs. price of CHF970.00 (13% below fair value)
Industry Position: 856.7% above the Drug Manufacturers median (#200 of 942)
No single metric tells the full story. See the XSWX:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
100GF Score
Get the complete analysis for XSWX:LLY
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:LLY has been successfully added to your 
